Relay Therapeutics (RLAY) Accounts Payables (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Accounts Payables data on file, last reported at $4.1 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $4.1 million, down 51.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.1 million (down 51.43% YoY), and the FY2025 annual result was $7.7 million, down 45.34% from the prior year.
• Accounts Payables declined to $4.1 million in Q1 2026 per RLAY's latest filing, from $7.7 million in the prior quarter.
• Over five years, Accounts Payables peaked at $14.8 million in Q2 2023 and troughed at $2.8 million in Q3 2025.
• A 5-year average of $8.8 million and a median of $8.4 million in 2025 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables surged 243.99% in 2023, then tumbled 59.92% in 2025.
• A 5-year view of Accounts Payables shows it stood at $10.6 million in 2022, then declined by 12.92% to $9.2 million in 2023, then soared by 53.05% to $14.1 million in 2024, then tumbled by 45.34% to $7.7 million in 2025, then sank by 46.74% to $4.1 million in 2026.
• Business Quant data shows RLAY's Accounts Payables at $4.1 million in Q1 2026, $7.7 million in Q4 2025, and $2.8 million in Q3 2025.